NCT04657302 2024-01-19A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaHoffmann-La RochePhase 1 Completed30 enrolled